Skip to content
Screener

Monopar Therapeutics MNPR Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$24.5B-7.3%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.26B-3.2%
Wave Life Sciences logo
Wave Life SciencesWVE
$558.32M+121%
Prime Medicine logo
Prime MedicinePRME
$249.04M-10.7%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$798.6M+307%
Enterprise value$746.28M+378%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0.0×
Current ratio56×

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 2:00 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001437749-26-016982
Line itemMarch 31, 2026December 31, 2025*
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock, par value of $0.001 per share, 40,000,000 shares authorized, 6,699,062 and 6,692,140 shares issued and outstanding at March 31, 2026, and December 31, 2025, respectively6,6996,692
Additional paid-in capital228,691,772227,199,002
Accumulated other comprehensive income (loss)98,521131,389
Retained earnings (accumulated deficit)(93,402,580)(89,509,530)
Total stockholders’ equity135,394,412137,827,553
Total liabilities and stockholders’ equity$137,983,725$140,717,709

Document

FAQ

What is Monopar Therapeutics's total liabilities & equity?
Monopar Therapeutics (MNPR) reported total liabilities & equity of $137.98M in Q1 2026.
How has Monopar Therapeutics's total liabilities & equity changed year-over-year?
Monopar Therapeutics's total liabilities & equity increased by 150.5% year-over-year, from $55.09M to $137.98M.
What is the long-term trend for Monopar Therapeutics's total liabilities & equity?
Over 5 years (2020 to 2025), Monopar Therapeutics's total liabilities & equity has grown at a 52.8% compound annual growth rate (CAGR), from $16.87M to $140.72M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Monopar Therapeutics's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude